5 Insightful Analyst Questions From Repligen's Q1 Earnings Call

Repligen’s first quarter results for 2025 saw revenue and adjusted profits exceed Wall Street expectations, but the market reacted negatively, reflecting investor caution. Management attributed growth to strong demand across its protein, chromatography, and analytics product lines, as well as robust order momentum in biopharma manufacturing. CEO Olivier Loeillot highlighted that "orders were up high teens year on year with all franchises growing double digits," and noted particularly strong performance from consumables and proteins. However, capital equipment sales faced headwinds due to timing and customer delays, while small biotech sales softened, highlighting ongoing uncertainty in that segment.

Is now the time to buy RGEN? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Repligen’s Q1 Earnings Call

• Rachel Vatnsdal (JPMorgan) asked whether tariffs led to order pull-forward and about the sustainability of CDMO order strength. CEO Olivier Loeillot replied there was no evidence of customers accelerating purchases and that CDMO growth was broad-based, especially in ATF consumables.
• Dan Arias (Stifel) inquired about emerging modalities and potential impacts from FDA changes. Loeillot confirmed new modalities revenue and orders rose, and reported no signs of trial disruptions or slowdowns from regulatory changes.
• Puneet Souda (Leerink Partners) questioned the clinical versus commercial revenue mix’s sustainability and the integration of 908 Devices. Loeillot explained the mix remains stable but is gradually shifting commercial, and integration efforts are focused on R&D and commercial synergy.
• Jacob Johnson (William Blair) asked about small biotech trends. Loeillot acknowledged sales to small biotech declined due to weak funding, but this segment now represents less than 10% of Repligen’s business.
• Justin Bowers (Deutsche Bank) asked about the impact of biopharma onshoring and margin outlook. Loeillot highlighted that increased U.S. manufacturing capacity could be a tailwind, and Garland noted Q1 gross margin benefited from product mix that is unlikely to repeat.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) the pace of adoption for new analytics and mixing technologies, (2) the trajectory of order growth among large pharma, CDMO, and emerging modalities, and (3) signs of stabilization or recovery in small biotech and China segments. Progress on integrating recent acquisitions and managing tariff-related risks will also be important markers for execution.

Repligen currently trades at $123.96, down from $143.71 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.